^
    Apply
    A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer (NCT04474470)
    Phase 1/2
    TyrNovo Ltd.
    Active, not recruiting
    Last update posted :
    05/09/2024
    Initiation :
    09/03/2020
    Primary completion :
    05/08/2024
    Completion :
    06/01/2024
    KRAS • BRAF
    |
    KRAS wild-type • RAS wild-type • RAS wild-type + BRAF wild-type
    |
    Erbitux (cetuximab) • NT219